<DOC>
	<DOCNO>NCT01693562</DOCNO>
	<brief_summary>This multicenter , open-label , first-time-in-human study standard 3+3 dose-escalation phase subject advance solid tumor follow expansion phase patient advance solid tumor . An exploration cohort add determine safety use Q4W dosing .</brief_summary>
	<brief_title>A Phase 1/2 Study Evaluate MEDI4736</brief_title>
	<detailed_description>A dose-escalation dose-expansion study MEDI4736 ( monoclonal antibody target program cell death-1 ligand 1 ( PD-L1 ) ) evaluate safety , tolerability , PK , IM , antitumor activity MEDI4736 adult patient solid tumor . A dose exploration cohort look safety profile Q4W dose MEDI4736 .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age 18 older . In doseescalation phase : histologically cytologically confirm advanced solid tumor refractory standard therapy standard therapy exist . In doseexpansion phase : histologically cytologically confirm advanced solid tumor approve firstline therapy available , subject must fail , intolerant , ineligible , refuse Eastern Cooperative Oncology Group ( ECOG ) status 0 1 . Adequate organ marrow function . Subjects must least 1 measurable lesion . Available archived tumor tissue sample . Willingness provide consent biopsy sample ( doseexpansion ) Any prior Grade â‰¥ 3 irAE receiving immunotherapy Prior exposure antiPD1 antiPDL1 antibody Any concurrent chemotherapy , immunotherapy , biologic hormonal therapy cancer treatment . Prior treatment immunotherapy agent include , limited , tumor necrosis factor receptor superfamily agonist checkpoint inhibitor natural killer ( NK ) cell inhibitor . Active prior document autoimmune disease within past 2 year History primary immunodeficiency History organ transplant require use immunosuppressive Symptomatic untreated central nervous system ( CNS ) metastases require concurrent treatment Other invasive malignancy within 2 year Women pregnant lactate Uncontrolled intercurrent illness Known history tuberculosis Known human immunodeficiency virus ( HIV ) positive Known Hepatitis B C positive ( except HCC patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced solid tumor</keyword>
</DOC>